What's moving in healthcare compliance.
Three layers, from short to long: the three weekly intelligence products, the full regulatory tracker behind them, and practical articles on what the rules actually require.
Three weekly products.
Recurring recaps of what moved across HHS, OCR, DOJ, OIG, CMS, DHCS, and California. The Regulatory Compliance Sweep covers new and changing obligations. The Enforcement Intelligence Briefing covers settlements, resolutions, and corporate integrity agreements. Medicare & Medicaid Actionable Updates covers government-payer developments and what operations has to do about them.
Every tracked development.
Tracked developments in compliance, privacy, and fraud-and-abuse regulation, with a plain read on what each one means for the organizations we serve.
Reviewed through August 2026
Entries reflect publicly reported regulatory developments and are summarized for general awareness. They are not legal advice, and details and effective dates change. Verify current requirements with primary sources and qualified counsel before acting.
Longer reads on what the rules require.
Practical perspective on the regulations and enforcement trends that shape how a compliance program gets run.
Show me this working in the last ninety days
Most programs can name the OIG's seven elements. Far fewer can show them operating. Here's how to tell the difference during a gap analysis.
PrivacyHIPAA is the floor. In California, CMIA is the ceiling.
Why provider networks that build only to the federal standard still carry real exposure under California's stricter privacy regime, and where the gaps usually hide.
AI governanceYou don't need an AI governance framework. You need your compliance program.
Ambient scribes and AI coding tools are arriving faster than the contracts covering them. A mapping of each OIG element onto AI risk, and the five places the fit is genuinely imperfect.
Risk defenseReading a physician arrangement before Stark reads it for you
A field guide to the transaction reviews that keep fair-market-value and commercial-reasonableness questions from becoming enforcement questions.